TNO155X
Total Payments
$1.1M
Transactions
10
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $444,029 | 3 | 0 |
| 2019 | $293,199 | 3 | 0 |
| 2018 | $222,979 | 2 | 0 |
| 2017 | $116,374 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN LABEL MULTI CENTER PHASE I DOSE FINDING STUDY OF ORAL TNO155 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $1.1M | 0 |
Top Doctors Receiving Payments for TNO155X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $1.1M | 10 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 0
- Transactions 10
About TNO155X
TNO155X is a drug associated with $1.1M in payments to 0 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $444,029 was paid across 3 transactions to 0 doctors.
The most common payment nature for TNO155X is "Unspecified" ($1.1M, 100.0% of total).
TNO155X is associated with 1 research study, including "AN OPEN LABEL MULTI CENTER PHASE I DOSE FINDING STUDY OF ORAL TNO155 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS" ($1.1M).